In an attempt to tackle GB progression, precision medicine targeting tumor vasculature (Bevacizumab vascular endothelial growth factor/VEGF scavenger antibody), tumor recurrence (Imatinib, platelet derived growth factor receptor/PDGFR inhibitor) or mitotic stromal and neoplastic cells (Enzastaurin, cytostatic and antiangiogenic), have been introduced to the clinics as monotherapy or in combination with a secondary agent in GB clinical trials.[8, 9] However, none of these attempts have yielded significant improvement of the progression‐free patient survival. This evidence concerns the gene VEGFA and neoplasm.